After some pharmacies and hospitals reported running out of Moderna’s omicron-targeted booster, the FDA authorized five lots of the product made at the drugmaker’s Bloomington, Ind., facility, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback